[HTML][HTML] Pharmacokinetic profile of gilteritinib: a novel FLT-3 tyrosine kinase inhibitor
…, K Souda, M Patton, Z Lu, C Liu, S Moy… - Clinical …, 2020 - Springer
Background and Objective Gilteritinib is a novel, highly selective tyrosine kinase inhibitor
approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 …
approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 …
[PDF][PDF] Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder
…, D Kowalski, T Drogendijk, S Moy… - Int J Clin Pharmacol …, 2012 - researchgate.net
Background and objectives: Mirabegron is a potent and selective β3-adrenoceptor agonist
in development for treatment of overactive bladder. Methods: Mirabegron pharmacokinetics …
in development for treatment of overactive bladder. Methods: Mirabegron pharmacokinetics …
Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the In Vivo Metabolism of Mirabegron, a β3-Adrenoceptor Agonist
J Lee, S Moy, J Meijer, W Krauwinkel… - Clinical drug …, 2013 - Springer
Background Mirabegron is a β 3 -adrenoceptor agonist for the treatment of overactive
bladder. There has been little information published or presented about the involvement of …
bladder. There has been little information published or presented about the involvement of …
An HPLC/MS/MS assay for tacrolimus in patient blood samples Correlation with results of an ELISA assay
AM Alak, S Moy, M Cook, P Lizak… - … of pharmaceutical and …, 1997 - Elsevier
An HPLC/MS/MS assay for tacrolimus in whole blood using FR900520 as an internal standard
was validated over the standard curve range of 0.100–10.040 ng ml −1 . The calibration …
was validated over the standard curve range of 0.100–10.040 ng ml −1 . The calibration …
Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron
…, M Schaddelee, J Keirns, V Kerbusch, S Moy… - Clinical drug …, 2013 - Springer
Background and Objectives Mirabegron, a selective β3-adrenoceptor agonist for the treatment
of overactive bladder (OAB), is eliminated by renal and metabolic routes. The potential …
of overactive bladder (OAB), is eliminated by renal and metabolic routes. The potential …
Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults
J Lee, W Zhang, S Moy, D Kowalski, V Kerbusch… - Clinical …, 2013 - Elsevier
BACKGROUND: Mirabegron is a β 3 -adrenoceptor agonist used for the treatment of overactive
bladder. Mirabegron is formulated as an extended-release tablet using oral controlled-…
bladder. Mirabegron is formulated as an extended-release tablet using oral controlled-…
Pharmacokinetics and bioequivalence of isavuconazole administered as isavuconazonium sulfate intravenous solution via nasogastric tube or orally in healthy …
A Desai, M Helmick, N Heo, S Moy… - Antimicrobial Agents …, 2021 - Am Soc Microbiol
For critically ill patients with invasive fungal infections, a nasogastric (NG) tube can be an
alternative route for administration of isavuconazonium sulfate (ISAVUSULF). This was a …
alternative route for administration of isavuconazonium sulfate (ISAVUSULF). This was a …
Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females
…, T Hatta, A Kaibara, M Katashima, S Moy… - Drug Metabolism and …, 2016 - Elsevier
Mirabegron, the first selective β 3 -adrenoceptor agonist for the treatment of overactive
bladder (OAB), inhibits cytochrome P450 isozyme CYP2D6. This study was performed in …
bladder (OAB), inhibits cytochrome P450 isozyme CYP2D6. This study was performed in …
Effect of enzalutamide on PK of P‐gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters
…, P Manchandani, N Heo, S Moy… - Clinical and …, 2022 - Wiley Online Library
Drug‐drug interaction (DDI) is an important consideration for clinical decision making in
prostate cancer treatment. The objective of this study was to evaluate the effect of enzalutamide, …
prostate cancer treatment. The objective of this study was to evaluate the effect of enzalutamide, …
Time-Dependent Inhibitory Effects of (1R, 9S, 12S, 13R, 14S, 17R, 18E, 21S, 23S, 24R, 25S, 27R)-1, 14-Dihydroxy-12-(E)-2-[(1R, 3R, 4R)-4-hydroxy-3 …
T Minematsu, J Lee, J Zha, S Moy, D Kowalski… - Drug metabolism and …, 2010 - ASPET
We investigated the inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,
14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,…
14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,…